Admera Health Company Profile

Background

Overview

Admera Health, established in 2014 as a spinout from Genewiz, is a New Jersey-based advanced molecular diagnostics company specializing in personalized medicine and non-invasive cancer testing. The company offers a comprehensive suite of genomic testing services, including whole-genome sequencing (WGS), RNA sequencing (RNA-seq), whole-genome bisulfite sequencing (WGBS), single-cell RNA sequencing, and whole-exome sequencing (WES). All services are conducted in a CLIA/CLEP-certified and CAP-accredited laboratory, ensuring high-quality results.

Mission and Vision

Admera Health is committed to advancing research through expert scientific support and advanced laboratory services. By leveraging genomic expertise and advanced bioinformatics, the company aims to provide innovative solutions for researchers and biopharmaceutical companies, ranging from exploratory studies to clinical applications.

Industry Significance

Operating in the biotechnology research sector, Admera Health plays a pivotal role in the field of genomics, offering services that support drug discovery, therapeutic development, companion diagnostics, and biomarker detection. The company's expertise in next-generation sequencing (NGS) technologies positions it as a valuable partner for academic institutions, biotech firms, and pharmaceutical companies.

Key Strategic Focus

Core Objectives

Advancement of Genomic Research: Provide high-quality genomic testing services to support a wide range of research applications.

Innovation in Laboratory Services: Utilize cutting-edge technologies to enhance the efficiency and accuracy of genomic analyses.

Global Expansion: Extend the company's reach through strategic partnerships and acquisitions to serve a broader international clientele.

Areas of Specialization

Next-Generation Sequencing (NGS): Offer comprehensive NGS services, including WGS, RNA-seq, WGBS, single-cell RNA-seq, and WES.

Bioinformatics Analysis: Provide advanced bioinformatics support to interpret complex genomic data effectively.

Clinical Laboratory Testing: Conduct clinical laboratory testing services related to pharmacogenetics, analyzing how genetic attributes affect responses to therapeutic drugs.

Key Technologies Utilized

EchoLUTION™ Technology: Following the acquisition of BioEcho Life Sciences in October 2024, Admera Health integrated the EchoLUTION™ nucleic acid purification technology, enhancing DNA and RNA extraction processes.

NovaSeq X Plus: In April 2025, Admera Health expanded its WGS capabilities by implementing the NovaSeq X Plus system, improving sequencing efficiency and output.

Primary Markets Targeted

Academic Institutions: Collaborate with universities and research hospitals to support genomic research initiatives.

Biotech and Pharmaceutical Companies: Provide services that aid in drug discovery, therapeutic development, and companion diagnostics.

Clinical Laboratories: Offer testing services that assist in personalized medicine and patient care.

Financials and Funding

Funding History

Admera Health has secured funding through private investments, including a Series A round. Specific details regarding the total funds raised and notable investors are not publicly disclosed.

Recent Funding Rounds

Information about recent funding rounds is not publicly available.

Utilization of Capital

The capital raised has been utilized to:

Expand Service Offerings: Enhance genomic testing capabilities and bioinformatics support.

Invest in Technology: Acquire advanced technologies like EchoLUTION™ and NovaSeq X Plus to improve service efficiency.

Support Global Expansion: Fund strategic acquisitions and partnerships to broaden the company's international presence.

Pipeline Development

Key Pipeline Candidates

Admera Health's pipeline includes:

PGxOne™ Plus: A pharmacogenomics test that analyzes over 50 genes and provides recommendations for over 300 drugs, aiding in personalized medicine.

OncoGxOne™ and OncoGxSelect™: Tumor profiling tests designed to guide the selection of targeted therapies and cancer supportive care.

Stages of Development

These tests are in the commercial stage, with established clinical applications and ongoing enhancements.

Target Conditions

Pharmacogenetics: Understanding how genetic variations affect individual responses to drugs.

Oncology: Identifying genetic mutations in tumors to inform treatment decisions.

Anticipated Milestones

Regulatory Approvals: Achieve necessary certifications and approvals for new tests.

Market Expansion: Increase adoption of tests in clinical settings and research institutions.

Technological Platform and Innovation

Proprietary Technologies

EchoLUTION™ Technology: A one-step extraction process that simplifies and enhances the yield and purity of DNA and RNA, integrated into Admera Health's services post-acquisition of BioEcho Life Sciences.

Significant Scientific Methods

Next-Generation Sequencing (NGS): Utilized for comprehensive genomic analyses, including WGS, RNA-seq, WGBS, single-cell RNA-seq, and WES.

Bioinformatics Analysis: Advanced computational methods to interpret complex genomic data, supporting research and clinical applications.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, Admera Health's integration of advanced technologies like EchoLUTION™ and NovaSeq X Plus indicates a commitment to leveraging cutting-edge tools to enhance genomic research and diagnostics.

Leadership Team

Key Executives

Yun Zhao, MD: Chief Executive Officer (CEO). Dr. Zhao has been instrumental in leading Admera Health's strategic direction and technological advancements.

James J. Dermody, PhD, ABMGG, ACMG: Laboratory Director. Dr. Dermody oversees laboratory operations, ensuring adherence to high-quality standards.

Leadership Changes

No recent significant changes or appointments within the company's leadership have been publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The molecular diagnostics market is experiencing significant growth, driven by advancements in genomic technologies and an increasing emphasis on personalized medicine. Companies like Admera Health are well-positioned to capitalize on this trend by offering comprehensive genomic testing services.

Competitor Analysis

Admera Health's key competitors include:

MedGenome: Specializes in genomic research and diagnostics, particularly in the areas of oncology and inherited diseases.

Neogenestar: Focuses on genomic testing services, offering solutions for various research and clinical applications.

Oneome: Provides pharmacogenomic testing services to guide medication decisions based on individual genetic profiles.

Strategic Collaborations and Partnerships

BioEcho Life Sciences: Acquired in October 2024, enhancing Admera Health's nucleic acid extraction capabilities.

MedCDx: Entered into a strategic partnership in February 2019 to co-develop companion diagnostics, expanding Admera Health's presence in the Asian market.

Rosetta Genomics: Collaborated in November 2014 for the commercialization of sequencing-based oncology tests, leveraging Rosetta's commercial infrastructure.

Operational Insights

Admera Health's strategic collaborations and acquisitions have strengthened its market position by expanding service offerings, enhancing technological capabilities, and increasing global reach.

Strategic Opportunities and Future Directions